The BRI Blog
For recent medical community news and insights, engage with our recent posts below.
Sally Pipes: “CMS Officials Are Undermining Trump’s Push For Affordable Drugs”
February 2, 2026 by bmew
Fierce competition for market share leads to massive discounting. In 2024 alone, biosimilars saved the U.S. healthcare system an estimated $20 million. Government price controls, however, impede market forces–and innovation.
Sally Pipes: “Sorry, But Single-Payer Won’t Fix American Health Care”
February 2, 2026 by bmew
The American health care system in its current form is not perfect. But Trading our system for one that routinely delays care, rations treatment and leaves patients dying in hallways would be a grave mistake.
Sally Pipes: “Proposed Patent Tax Offers a Dangerous ‘Solution’ to a Non-Existent Problem”
January 27, 2026 by bmew
When you tax something, you tend to get a lot less of it. Why, then, does U.S. Commerce Secretary Howard Lutnick believe that the federal government should be taxing universities at an exorbitant 50% rate for licensing their patent discoveries?
Sally Pipes: “The ‘Medicare-For-All’ Delusion”
January 26, 2026 by bmew
Is the nation in a place to allocate $30-$35 trillion in new federal spending for the first decade of a policy which results in resources, shortages, delays, rationing, and worse care for patients everywhere it’s tried?
January 22, 2026 by bmew
A study published this week by the Pacific Research Institute found that the return on capital for health insurers and PBMs is four times higher than it is for drug manufacturers. Yet, so often, we’re told biopharmaceutical companies are the ones earning excessive returns.
Sally Pipes: “Enhanced Obamacare Subsidies are Gone. They Deserve to Stay That Way.”
January 22, 2026 by bmew